Sign In
Buy GSK
$50.67
-1.48 (-2.84%)
At Close: Jun 18, 2026
Pharma Stock Roundup: FDA Nod for 2nd COVID Booster, New Approvals for AZN, GSK, NVS
01:09pm, Friday, 01'st Apr 2022 Zacks Investment Research
FDA authorizes second booster dose of PFE and MRNA COVID-19 vaccines for older adults. RHHBY's late-stage study for ES-SCLC fails.
GlaxoSmithKline (GSK) Stock Moves -0.32%: What You Should Know
09:45pm, Thursday, 31'st Mar 2022 Zacks Investment Research
GlaxoSmithKline (GSK) closed the most recent trading day at $43.56, moving -0.32% from the previous trading session.
Adagio's (ADGI) COVID-19 Antibody Meets Goals in Studies
04:14pm, Thursday, 31'st Mar 2022 Zacks Investment Research
The stock price of Adagio (ADGI) surge after it reports positive preliminary data from the phase II/III studies, which evaluate its monoclonal antibody for the prevention and treatment of COVID-19.
VIR Stock Gains on News of Inclusion in the S&P SmallCap 600
03:23pm, Thursday, 31'st Mar 2022 Zacks Investment Research
Vir Biotechnology (VIR) shares gain as the company is set to join the S&P SmallCap 600 effective prior to the opening of trading on Monday, Apr 4.
WHO urges countries to keep up COVID-19 testing and surveillance as the viral outbreak remains a global pandemic
12:07pm, Thursday, 31'st Mar 2022 MarketWatch
The World Health Organization said Wednesday it's increasingly concerned at the reduction in COVID-19 testing, surveillance and overall monitoring among its member countries, reminding the public that
J&J (JNJ) Gets FDA Nod for HIV Jab, Cabenuva, in Adolescents
04:28pm, Wednesday, 30'th Mar 2022 Zacks Investment Research
The FDA approves Johnson & Johnson's (JNJ) Cabenuva for treating HIV-1 in virologically suppressed adolescents aged 12 years and above.
AstraZeneca (AZN) Gets EU Nod for COVID-19 Antibody Cocktail
04:31pm, Monday, 28'th Mar 2022 Zacks Investment Research
The European Commission approves AstraZeneca's (AZN) Evusheld for the pre-exposure prophylaxis of COVID-19 infection in a broad patient population.
FDA Revises EUA of Glaxo (GSK) & Vir's (VIR) COVID Therapy
03:41pm, Monday, 28'th Mar 2022 Zacks Investment Research
The FDA restricts the use of sotrovimab, Glaxo (GSK)/Vir's (VIR) COVID therapy, in several states and territories based on the latest data that does not support the therapy's effectiveness against a d
Are These 2 Rivals Beating Pfizer and Moderna?
10:00am, Monday, 28'th Mar 2022 The Motley Fool
They're winning when it comes to orders.
Which Company Has the Biggest COVID Program? The Answer Isn't Moderna.
12:00pm, Sunday, 27'th Mar 2022 The Motley Fool
Another player has stuffed its pipeline with many coronavirus candidates.
GlaxoSmithKline (GSK) Stock Sinks As Market Gains: What You Should Know
09:45pm, Friday, 25'th Mar 2022 Zacks Investment Research
GlaxoSmithKline (GSK) closed at $43.28 in the latest trading session, marking a -0.05% move from the prior day.
These 3 Stocks Aren't Large Caps Yet, but They Each Could Make $1 Billion in Sales in 2022
08:00pm, Friday, 25'th Mar 2022 The Motley Fool
Looking for small healthcare companies with huge revenue opportunities? Try these.
Pfizer's (PFE) RSV Jab Gets Another Breakthrough Therapy Tag
03:03pm, Friday, 25'th Mar 2022 Zacks Investment Research
The FDA bestows another Breakthrough Therapy status to Pfizer's (PFE) RSV vaccine candidate, RSVpreF, for the prevention of RSV in older adults.
Halozyme (HALO) Inks Collaboration Deal With Chugai Pharma
01:47pm, Friday, 25'th Mar 2022 Zacks Investment Research
Halozyme (HALO) and Japan-based Chugai Pharma sign a collaboration agreement, which gives the latter an exclusive right to Halozyme's ENHANZE technology to develop a therapy for an undisclosed target.
Where to Invest $100 Right Now
01:00pm, Friday, 25'th Mar 2022 The Motley Fool
A little bit of money can go a long way with thorough research and smart investments.
